These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25209378)

  • 1. Historical data analyses and scientific knowledge suggest complete removal of the abnormal toxicity test as a quality control test.
    Garbe JHO; Ausborn S; Beggs C; Bopst M; Joos A; Kitashova AA; Kovbasenco O; Schiller CD; Schwinger M; Semenova N; Smirnova L; Stodart F; Visalli T; Vromans L
    J Pharm Sci; 2014 Nov; 103(11):3349-3355. PubMed ID: 25209378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three Rs potential in the development and quality control of immunobiologicals.
    Halder M
    ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Removal of the innocuity test from The International Pharmacopoeia and WHO recommendations for vaccines and biological products.
    Lei D; Schmidt H; Knezevic I; Zhou T; Kang HN; Kopp S
    Biologicals; 2020 Jul; 66():17-20. PubMed ID: 32536585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacement, Reduction, Refinement - Animal welfare progress in European Pharmacopoeia monographs: activities of the European Pharmacopoeia Commission from 2007 to 2017.
    Lang C; Kolaj-Robin O; Cirefice G; Taconet L; Pel E; Jouette S; Buda M; Milne C; Charton E
    Pharmeur Bio Sci Notes; 2018; 2018():12-36. PubMed ID: 29845933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calibration of the Ph. Eur. Biological Reference Preparation (BRP) for tetanus vaccine (adsorbed) batch 3.
    Tierney R; Hockley J; Rigsby P; Terao E; Daas A; Buchheit KH; Sesardic D
    Pharmeur Bio Sci Notes; 2011 Jun; 2011(1):1-26. PubMed ID: 21619853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the abnormal toxicity test still relevant for the safety of vaccines, sera and immunoglobulins?
    Krämer B; Nagel M; Duchow K; Schwanig M; Cussler K
    ALTEX; 1996; 13(1):7-16. PubMed ID: 11178440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacopoeia as quality codex for the manufacturers.
    Soldi A
    Ann Ist Super Sanita; 1975; 11(3-4):269-80. PubMed ID: 1234728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An improved abnormal toxicity test by using reference vaccine-specific body weight curves and histopathological data for monitoring vaccine quality and safety in Japan.
    Mizukami T; Masumi A; Momose H; Kuramitsu M; Takizawa K; Naito S; Maeyama J; Furuhata K; Tsuruhara M; Hamaguchi I; Yamaguchi K
    Biologicals; 2009 Jan; 37(1):8-17. PubMed ID: 18805705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global harmonization of vaccine testing requirements: Making elimination of the ATT and TABST a concrete global achievement.
    Viviani L; Halder M; Gruber M; Bruckner L; Cussler K; Sanyal G; Srinivas G; Goel S; Kaashoek M; Litthauer D; Lopes da Silva AL; Sakanyan E; Aprea P; Jin H; Vandeputte J; Seidle T; Yakunin D
    Biologicals; 2020 Jan; 63():101-105. PubMed ID: 31699501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. False positive findings associated with adenoviral vector-based vaccine underscore the regulatory necessity to eliminate abnormal toxicity test.
    Meng R; van Ooij M; Li Y; Zhang Y; Xie J
    Regul Toxicol Pharmacol; 2024 May; 149():105617. PubMed ID: 38561146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 4R concept for the safety testing of immunobiologicals.
    Cussler K
    Dev Biol Stand; 1999; 101():121-6. PubMed ID: 10566784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential confounding effects of benzyl alcohol as a formulation excipient support the elimination of the abnormal toxicity test from pharmacopoeias.
    Xie J; Ottaviani G; Sun K; Lu M; Wu X; Huang S; Bopst M
    Regul Toxicol Pharmacol; 2015 Nov; 73(2):509-14. PubMed ID: 26449397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Collaborative study for the standardisation of the histamine sensitizing test in mice and the CHO cell-based assay for the residual toxicity testing of acellular pertussis vaccines.
    Xing D; Maes A; Behr-Gross ME; Costanzo A; Daas A; Buchheit KH
    Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):51-63. PubMed ID: 20223190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
    Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
    PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern science for better quality control of medicinal products "Towards global harmonization of 3Rs in biologicals": The report of an EPAA workshop.
    Schutte K; Szczepanska A; Halder M; Cussler K; Sauer UG; Stirling C; Uhlrich S; Wilk-Zasadna I; John D; Bopst M; Garbe J; Glansbeek HL; Levis R; Serreyn PJ; Smith D; Stickings P
    Biologicals; 2017 Jul; 48():55-65. PubMed ID: 28596049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of QbD for the development of a vaccine candidate.
    Haas J; Franklin A; Houser M; Maraldo D; Mikola M; Ortiz R; Sullivan E; Otero JM
    Vaccine; 2014 May; 32(24):2927-30. PubMed ID: 24598725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Batch variability of bacitracin: HPLC versus MEKC.
    Weber C; Matingen S; Holzgrabe U
    Pharmeur Sci Notes; 2005 Aug; 2005(1):47-51. PubMed ID: 17687894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Industrial approaches and consideration of clinical relevance in setting impurity level specification for drug substances and drug products.
    Pokar D; Rajput N; Sengupta P
    Int J Pharm; 2020 Feb; 576():119018. PubMed ID: 31911117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organization
    World Health Organ Tech Rep Ser; 2014; (986):1-387, back cover. PubMed ID: 24964711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refinement, reduction, and replacement of animal use for regulatory testing: current best scientific practices for the evaluation of safety and potency of biologicals.
    Hendriksen CF
    ILAR J; 2002; 43 Suppl():S43-8. PubMed ID: 12388851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.